The widespread adoption of GLP-1 receptor agonists—the class of weight-loss jabs including Wegovy and Ozempic—could do more than just reduce waistlines; it may fundamentally alleviate the systemic pressure on the United Kingdom’s healthcare infrastructure. New research suggests that these medications could halve sickness absence among patients and significantly reduce the burden on the National Health Service (NHS), potentially freeing up millions of clinical appointments annually.
The findings, presented at the European Congress on Obesity in Istanbul, indicate that the impact of these drugs extends far beyond aesthetic weight loss, touching on critical metrics of economic productivity and primary care capacity. For a health system currently struggling with record waiting lists and workforce burnout, the potential to decouple obesity from frequent medical interventions offers a promising path toward sustainability.
As a physician, I have watched the conversation around these medications shift from “miracle drugs” to complex tools for metabolic health. The data now suggests that when weight-loss jabs and NHS strain are addressed through a combined clinical approach, the result is a measurable “return to life” for patients who previously struggled with multiple comorbidities.
Reducing the Burden of Sickness Absence
A study of 1,270 NHS patients enrolled in Oviva’s tier 3 weight management programme revealed a stark improvement in workplace attendance. The participants, all of whom suffered from at least three weight-related illnesses—most frequently high blood pressure, type 2 diabetes, and anxiety—were prescribed GLP-1 injections over a nine-month period.
The results showed that total sickness days fell by 45%. Even more significant was the impact on long-term health disruptions; sickness absences lasting five days or more dropped by 56%. This suggests that the medications are not merely treating symptoms but are improving the overall functional capacity of patients, allowing them to remain in the workforce.
On average, patients lost 12.4% of their total body weight, with average BMI figures dropping from 45 to 39. This physical change coincided with a dramatic shift in how patients interacted with the healthcare system. Face-to-face GP appointments decreased by an average of 43%, and remote consultations fell by 48%. Remarkably, more than 60% of the participants reported that they did not need to contact their GP at all during the study period.
Systemic Gains for Primary and Emergency Care
The implications for the broader NHS are substantial. While the primary study focused on GP interactions, a separate analysis of 738 patients found that A&E visits among those using the jabs fell by 25%. When scaled to the national level, the potential for systemic relief is immense.
With approximately 30% of adults in England classified as obese, the economic and operational arguments for expanded access are mounting. Experts suggest that if the programme were extended to the 3.4 million people currently eligible for these medications on the NHS, the service could save approximately £364 million per year—roughly 3% of the GP core budget—while freeing up nearly 10 million GP appointments annually.
| Metric | Reduction Observed |
|---|---|
| Total Sickness Days | 45% |
| Long-term Sick Leave (5+ days) | 56% |
| Face-to-Face GP Visits | 43% |
| Remote GP Consultations | 48% |
| A&E Attendance | 25% |
Martin Fidock, the UK managing director of Oviva, framed the issue as an economic necessity as much as a medical one. “Britain is in the grip of a productivity crisis, and obesity is one of the biggest drivers,” Fidock said. “Our data shows that when people get the right treatment – jabs combined with proper clinical support – they don’t just lose weight. They get back to work, stop relying on their GP and start living again.”
Dr. Charlotte Refsum, director of policy at the Tony Blair Institute, described the findings as “striking,” noting that broader access to anti-obesity medications could deliver significant gains for the economy alongside major savings for the NHS.
Unexpected Benefits: Asthma and Migraines
Beyond weight and workforce productivity, the European Congress on Obesity also featured two Danish studies suggesting that GLP-1 drugs may have systemic anti-inflammatory effects that benefit other chronic conditions. One study focused on patients with asthma who were also overweight, obese, or living with type 2 diabetes.
Researchers found that those taking semaglutide or liraglutide experienced a 26% reduction in asthma exacerbations, including hospitalisations. There was a 14% reduction in the use of asthma inhalers and a 23% decrease in daily inhaled corticosteroid exposure. Notably, pneumonia events were reduced by 10%. These effects were observed within a month of starting the medication, occurring before significant weight loss had taken place, which suggests a direct pharmacological benefit to the respiratory system.
A second Danish study looked at a younger demographic, finding that 18- to 35-year-olds using Wegovy for weight management saw an 18% reduction in the use of acute migraine triptan medication. While these findings are encouraging, researchers cautioned that further studies are required to establish the exact dose-effect and to see if these results can be replicated across all GLP-1 medications.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a licensed healthcare provider before starting or changing any medication.
The next phase of evaluation will likely focus on the long-term sustainability of these gains and the cost-effectiveness of expanding access to the millions of eligible patients currently on waiting lists. Public health officials are expected to monitor further longitudinal data on the “dose effect” regarding comorbidities like migraines and asthma to determine if these drugs can be repurposed for broader clinical use.
We want to hear from you. Do you believe the long-term savings to the NHS justify the high upfront cost of these medications? Share your thoughts in the comments or share this story with your network.
